Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
Study Details
Study Description
Brief Summary
In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
- Patients experience of self-administration of Velcade [Through study completion, from 01. dec. 2019 until 01. jun. 2022]
Qualitative interviews with all 10 included patients
Secondary Outcome Measures
- Organizational perspective [Through study completion, from 01. dec. 2019 until 01. jun. 2022]
Patients and health professionals (including pharmacy staff) registration of time spend on treatment on all 10 included patients.
- Health care perspective [Through study completion, from 01. dec. 2019 until 01. jun. 2022]
Focus group interview with healthcare professionals involved in the treatment.
- Financial perspective [Through study completion, from 01. dec. 2019 until 01. jun. 2022]
Evaluation of financial savings on home treatment including healthcare salaries and transportation.
Eligibility Criteria
Criteria
Inclusion criteria
-
Patients must have Multiple Myeloma
-
Patients (or their relatives) must be deemed physically and cognitively suitable and willing for self-administration of subcutaneous Velcade
-
Patients must be able to understand and speak Danish
-
Patients must have received a minimum of 1 treatment cycle in the outpatient clinic
Exclusion criteria
-
Lack of willingness to participate in scheduled interviews
-
Patients who are cognitively affected
-
Must not be receiving trial treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Odense University Hospital | Odense | Denmark | 5000 |
Sponsors and Collaborators
- Karin B. Ø. Dieperink
Investigators
- Study Director: Karin Brochstedt Dieperink, RN, Odense University Hospital. Department of Oncology.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HFE-X 20.01